MedTrace Logo

UV1 Vaccine With Pembrolizumab for Patients With Unresectable or Metastatic Melanoma

NCT03538314 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2024-08-22

No results posted yet for this study

Summary

UV1 is a therapeutic cancer vaccine that has been explored in prostate and lung cancers, and in combination with ipilimumab in malignant melanoma. This study will explore the safety, tolerability and efficacy of UV1 administered with GM-CSF in melanoma patients who are also receiving pembrolizumab.

Conditions

  • Malignant Melanoma

Interventions

DRUG

UV1

UV1 (300 microgram)

DRUG

GM-CSF

GM-CSF (37,5 or 75 microgram)

Sponsors & Collaborators

  • Ultimovacs ASA

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-07-09
Primary Completion
2022-10-01
Completion
2024-06-15
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03538314 on ClinicalTrials.gov